(Q48258954)

English

Systematic evaluation of augmentation during treatment with ropinirole in restless legs syndrome (Willis-Ekbom disease): results from a prospective, multicenter study over 66 weeks.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/22328464

Systematic evaluation of augmentation during treatment with ropinirole in restless legs syndrome (Willis-Ekbom disease): results from a prospective, multicenter study over 66 weeks. (English)

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/22328464

restless legs syndrome

1 reference

based on heuristic

inferred from title

Luigi Ferini Strambi

3

object named as

Luigi Ferini-Strambi

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

2

object named as

Birgit Högl

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

Richard P Allen

7

object named as

Richard Allen

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

author name string

Diego García-Borreguero

1

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/22328464

John Winkelman

4

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/22328464

Christina Hill-Zabala

5

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/22328464

Afsaneh Asgharian

6

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/22328464

language of work or name

0 references

publication date

4 January 2012

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/22328464

Movement Disorders

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/22328464

27

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/22328464

2

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/22328464

277-283

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/22328464

An algorithm for the management of restless legs syndrome

1 reference

https://api.crossref.org/works/10.1002%2FMDS.24889

21 January 2018

A 52-week open-label study of the long-term safety of ropinirole in patients with restless legs syndrome

1 reference

https://api.crossref.org/works/10.1002%2FMDS.24889

21 January 2018

Ropinirole is effective in the long-term management of restless legs syndrome: a randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1002%2FMDS.24889

21 January 2018

Ropinirole decreases periodic leg movements and improves sleep parameters in patients with restless legs syndrome

1 reference

https://api.crossref.org/works/10.1002%2FMDS.24889

21 January 2018

Treatment of restless legs syndrome: an evidence-based review and implications for clinical practice

1 reference

https://api.crossref.org/works/10.1002%2FMDS.24889

21 January 2018

Ropinirole is effective in the treatment of restless legs syndrome. TREAT RLS 2: a 12-week, double-blind, randomized, parallel-group, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1002%2FMDS.24889

21 January 2018

Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health

1 reference

https://api.crossref.org/works/10.1002%2FMDS.24889

21 January 2018

Diagnostic standards for dopaminergic augmentation of restless legs syndrome: report from a World Association of Sleep Medicine-International Restless Legs Syndrome Study Group consensus conference at the Max Planck Institute

1 reference

https://api.crossref.org/works/10.1002%2FMDS.24889

21 January 2018

The Johns Hopkins telephone diagnostic interview for the restless legs syndrome: preliminary investigation for validation in a multi-center patient and control population

1 reference

https://api.crossref.org/works/10.1002%2FMDS.24889

21 January 2018

Validation of the International Restless Legs Syndrome Study Group rating scale for restless legs syndrome

1 reference

https://api.crossref.org/works/10.1002%2FMDS.24889

21 January 2018

Validation of the Augmentation Severity Rating Scale (ASRS): a multicentric, prospective study with levodopa on restless legs syndrome

1 reference

https://api.crossref.org/works/10.1002%2FMDS.24889

21 January 2018

Loss of response during long-term treatment of restless legs syndrome: guidelines approved by the International Restless Legs Syndrome Study Group for use in clinical trials.

1 reference

https://api.crossref.org/works/10.1002%2FMDS.24889

21 January 2018

Efficacy and augmentation during 6 months of double-blind pramipexole for restless legs syndrome.

1 reference

https://api.crossref.org/works/10.1002%2FMDS.24889

21 January 2018

Augmentation in restless legs syndrome is associated with low ferritin

1 reference

https://api.crossref.org/works/10.1002%2FMDS.24889

21 January 2018

Augmentation and tolerance with long-term pramipexole treatment of restless legs syndrome (RLS).

1 reference

https://api.crossref.org/works/10.1002%2FMDS.24889

21 January 2018

Restless legs syndrome (RLS) augmentation associated with dopamine agonist and levodopa usage in a community sample

1 reference

https://api.crossref.org/works/10.1002%2FMDS.24889

21 January 2018

A 10-year, longitudinal assessment of dopamine agonists and methadone in the treatment of restless legs syndrome.

1 reference

https://api.crossref.org/works/10.1002%2FMDS.24889

21 January 2018

Identifiers

10.1002/MDS.24889

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/22328464

release_6s2pf543gnfzhakkbk3m5jrc5q

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/22328464

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q48258954&oldid=1519541554"